Phase II COVID-19 placenta cellular therapy trial to launch in IsraelPluristem is treating COVID-19 patients with its PLX-PAD novel, placenta-derived cellular therapy.A Pluristem bio-reactor in action(photo credit: PLURISTEM THERAPEUTICS INC.)
A Pluristem bio-reactor in action(photo credit: PLURISTEM THERAPEUTICS INC.)